Kaye K W, Lightner D J
Department of Urology, Abbott Northwestern Hospital, Minneapolis, Minnesota.
Urology. 1993 May;41(5):417-20. doi: 10.1016/0090-4295(93)90499-z.
With increasing use of transrectal ultrasonography (TRUS) it becomes important to establish guidelines for its appropriate utilization. Three hundred and twenty-two patients with either an abnormal digital rectal examination (DRE) or prostate-specific antigen (PSA), or both, were evaluated further for cancer by means of prostatic ultrasonography. Two hundred and twenty-five (70%) of these underwent ultrasound-guided biopsy, cancer was detected in 74 (23%), and 33 percent of all biopsy specimens were positive. Thus, the indices of biopsy: TRUS (Bx:T), cancer: TRUS (Ca:T), and cancer: biopsy (Ca:Bx) were 70 percent, 23 percent, and 33 percent, respectively. Comparing these indices with other earlier series (TRUS used less selectively) and with more recent series (TRUS used more selectively), suggest that ratios in the range of biopsy: TRUS of 70 percent to 75 percent, cancer: TRUS of 25 percent to 30 percent, and cancer: biopsy of 30 percent to 40 percent may be expected with appropriate use of this imaging modality.
随着经直肠超声检查（TRUS）的使用日益增加，制定其合理应用的指南变得很重要。对322例直肠指检（DRE）异常或前列腺特异性抗原（PSA）异常或两者均异常的患者，通过前列腺超声检查进一步评估是否患有癌症。其中225例（70%）接受了超声引导下活检，74例（23%）检测到癌症，所有活检标本中有33%呈阳性。因此，活检：TRUS（Bx:T）、癌症：TRUS（Ca:T）和癌症：活检（Ca:Bx）的指标分别为70%、23%和33%。将这些指标与其他早期系列研究（TRUS使用选择性较低）以及最近的系列研究（TRUS使用选择性较高）进行比较，结果表明，合理使用这种成像方式时，活检：TRUS的比例可能在70%至75%之间，癌症：TRUS的比例在25%至30%之间，癌症：活检的比例在30%至40%之间。
